ProMIS Neurosciences Inc(PMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:53 PM ET (Korea 10/31 08:53)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -13.43 | Insider Own | 21.59% | Shs Outstand | 9.0M | Perf Week | -60.31% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 28.12% | Insider Trans | 0.12% | Shs Float | 7.0M | Perf Month | -64.71% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -1.28 | Inst Own | 60.8% | Short Float | 3.5% | Perf Quarter | -76.59% |
| Income | -0.04B | P/S | - | EPS this Y | 77.43% | Inst Trans | 0.76% | Short Ratio | 7.07 | Perf Half Y | -69.94% |
| Sales | 0.00B | P/B | 0.6 | EPS next 5Y | 49.66% | ROA | -127.57% | Short Interest | 0.25M | Perf YTD | -51.5% |
| Book/sh | 5.51 | P/C | 0.56 | EPS past 3/5Y | 27.86% -0.39% | ROE | -172.3% | 52W High | -87.92% ($27.40) | Perf Year | -68.3% |
| Cash/sh | 5.96 | P/FCF | - | Sales past 3/5Y | - | ROIC | -85.48% | 52W Low | -47.21% ($6.27) | Perf 3Y | -92.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -169.38% | Gross Margin | - | Volatility(W/M) | 47.19% 18.21% | Perf 5Y | -98.51% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.56 | Perf 10Y | -97.78% |
| Dividend Ex-Date | - | Quick Ratio | 7.85 | EPS Q/Q | 82.32% | Profit Margin | - | RSI (14) | 27.2 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.85 | Sales Q/Q | - | SMA20 | -62.32% ($8.78) | Beta | -0.28 | Target Price | $44.92 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -70.59% ($11.25) | Rel Volume | 47.16 | Prev Close | $11.08 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 7.15% - | SMA200 | -74.33% ($12.89) | Avg Volume(3M) | 0.03M | Price | $3.31 |
| IPO | 2007/1/16 | Option/Short | No/Yes | Trades | 7321 | Volume | 1,639,654 | Change | -70.13% |
🧠 This is a clinical-stage biotech developing antibodies to treat neurodegenerative diseases such as Alzheimer's and ALS. Using proprietary computational modeling technology, it designs antibodies that selectively target only the toxic protein clumps (oligomers). Its Alzheimer's treatment, PMN310, is currently in a Phase 1b clinical trial, and it also holds a pipeline for ALS and multiple system atrophy.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded more than usual. That is 4716% of its average volume.
PMN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +77.4% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 60.8%.
Tap to view numbers
It ranks #449 of 597 in the industry
Based on market cap of $30M.
EYPT#446 EyePoint Inc $30M PER - 
ALGS#447 Aligos Therapeutics Inc $30M PER - 
AARD#448 Aardvark Therapeutics Inc $30M PER - PMN#449 ProMIS Neurosciences Inc $30M PER - 
MGX#450 Metagenomi Therapeutics Inc $29M PER - 
FAQ
What kind of company is PMN?
PMN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PMN?
The market cap of PMN is approximately $30M, ranking 5,077 within its sector.
What is the 52-week high and low for PMN?
PMN has recorded a 52-week high of $27.40 and a low of $6.27.
